Paola Cafforio

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5717458/publications.pdf

Version: 2024-02-01

50 papers	2,009 citations	279798 23 h-index	243625 44 g-index
50 all docs	50 docs citations	50 times ranked	2939 citing authors

#	Article	IF	Citations
1	Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879463.	3.2	317
2	Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis, 2005, 26, 883-891.	2.8	230
3	Th1 polarization of the immune response in Behï¿½et's disease: A putative pathogenetic role of interleukin-12. Arthritis and Rheumatism, 1999, 42, 1967-1974.	6.7	210
4	Negative regulation of erythroblast maturation by Fas-L+/TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood, 2002, 99, 1305-1313.	1.4	97
5	Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. Aids, 1996, 10, 131-141.	2.2	94
6	Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. British Journal of Haematology, 2004, 126, 475-486.	2.5	90
7	In vitro differentiation of human oocyte-like cells from oogonial stem cells: single-cell isolation and molecular characterization. Human Reproduction, 2018, 33, 464-473.	0.9	90
8	Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. British Journal of Haematology, 2003, 122, 39-52.	2.5	65
9	PTHrP Produced by Myeloma Plasma Cells Regulates Their Survival and Pro-Osteoclast Activity For Bone Disease Progression. Journal of Bone and Mineral Research, 2014, 29, 55-66.	2.8	53
10	Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood, 2001, 97, 1155-1164.	1.4	51
11	CD8+ /CD57+ cells and apoptosis suppress T-cell functions in multiple myeloma. British Journal of Haematology, 1998, 100, 469-477.	2.5	49
12	Immature dendritic cells in multiple myeloma are prone to osteoclastâ€like differentiation through interleukinâ€17<scp>A</scp> stimulation. British Journal of Haematology, 2013, 161, 821-831.	2.5	42
13	Functional osteoclast-like transformation of cultured human myeloma cell lines. British Journal of Haematology, 2005, 130, 926-938.	2.5	39
14	Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG. Clinical and Experimental Immunology, 1996, 104, 91-97.	2.6	37
15	IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity. International Journal of Clinical and Laboratory Research, 1997, 27, 48-54.	1.0	32
16	Negative Regulation of the Osteoblast Function in Multiple Myeloma through the Repressor Gene E4BP4 Activated by Malignant Plasma Cells. Clinical Cancer Research, 2008, 14, 6081-6091.	7.0	32
17	Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-I) in active lupus. Lupus, 2003, 12, 8-14.	1.6	31
18	Perspective in infertility: the ovarian stem cells. Journal of Ovarian Research, 2015, 8, 55.	3.0	31

#	Article	IF	Citations
19	Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations. Clinical and Experimental Immunology, 2008, 97, 19-25.	2.6	29
20	Next-generation Sequencing (NGS) Analysis on Single Circulating Tumor Cells (CTCs) with No Need of Whole-genome Amplification (WGA). Cancer Genomics and Proteomics, 2017, 14, 173-179.	2.0	29
21	Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effect of Bortezomib and Lenalidomide. Leukemia Research, 2010, 34, 243-249.	0.8	27
22	Cross-linking of Fas By Antibodies to a Peculiar Domain of gp120 V3 Loop Can Enhance T Cell Apoptosis in HIV-1â€“infected Patients. Journal of Experimental Medicine, 1996, 184, 2287-2300.	8.5	26
23	Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells. Clinical and Experimental Immunology, 1998, 114, 179-188.	2.6	25
24	pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo. Stem Cell Research and Therapy, 2017, 8, 206.	5.5	25
25	Breast cancer: an update on treatment-related infertility. Journal of Cancer Research and Clinical Oncology, 2020, 146, 647-657.	2.5	25
26	Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro. Leukemia Research, 2008, 32, 611-623.	0.8	23
27	In Vitro Generation of Oocytes from Ovarian Stem Cells (OSCs): In Search of Major Evidence. International Journal of Molecular Sciences, 2019, 20, 6225.	4.1	23
28	Osteoclast-like Cell Formation by Circulating Myeloma B Lymphocytes: Role of RANK-L. Leukemia and Lymphoma, 2004, 45, 377-380.	1.3	16
29	Dissection of major cancer gene variants in subsets of circulating tumor cells in advanced breast cancer. Scientific Reports, 2019, 9, 17276.	3.3	16
30	Functional Fas-ligand expression on T cells from HIV-1-infected patients is unrelated to CD4+ lymphopenia. International Journal of Clinical and Laboratory Research, 1998, 28, 215-225.	1.0	11
31	In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1921-1931.	1.3	11
32	1,25(OH)2 vitamin D(3) contributes to osteoclast-like trans-differentiation of malignant plasma cells. Experimental Cell Research, 2017, 358, 260-268.	2.6	11
33	Ddx4+ Oogonial Stem Cells in Postmenopausal Womenâ€™s Ovaries: A Controversial, Undefined Role. Cells, 2019, 8, 650.	4.1	11
34	Anemia in Multiple Myeloma: Role of Deregulated Plasma Cell Apoptosis. Leukemia and Lymphoma, 2002, 43, 1527-1533.	1.3	10
35	Cilengitide restrains the osteoclastâ€like bone resorbing activity of myeloma plasma cells. British Journal of Haematology, 2016, 173, 59-69.	2.5	10
36	Dual-procedural separation of CTCs in cutaneous melanoma provides useful information for both molecular diagnosis and prognosis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592090541.	3.2	10

#	Article	IF	Citations
37	Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases. British Journal of Cancer, 2022, 126, 419-429.	6.4	10
38	Serum elevations of soluble Fas (CD95/apo-I) concur in deregulating T cell apoptosis during active lupus disease. Clinical and Experimental Medicine, 2002, 2, 13-27.	3.6	9
39	Functional expression of the calcitonin receptor by human T and B cells. Human Immunology, 2009, 70, 678-685.	2.4	9
40	Liquid Biopsy in Cervical Cancer: Hopes and Pitfalls. Cancers, 2021, 13, 3968.	3.7	9
41	VEINCTR-N, an Immunogenic Epitope of Fas (CD95/Apo-I), and Soluble Fas Enhance T-cell Apoptosis in vitro. II. Functional Analysis and Possible Implications in HIV-1 Disease. Molecular Medicine, 2000, 6, 509-526.	4.4	8
42	Molecular Specificities of CD4+ T Cell-Reactive IgM in Human Immunodeficiency Virus (HIV-1) Infection. Clinical Immunology and Immunopathology, 1994, 70, 40-46.	2.0	7
43	Circulating tumor cells from melanoma patients show phenotypic plasticity and metastatic potential in xenograft NOD.CB17 mice. BMC Cancer, 2022, 22, .	2.6	6
44	LFA-1 expression on CD4+CD45RO+ peripheral blood T-lymphocytes in RR MS: effects induced by rIFNÎ²-1a. Journal of the Neurological Sciences, 2001, 186, 65-73.	0.6	5
45	Immunogenicity of an Eight Amino Acid Domain Shared by Fas (CD95/Apo-I) and HIV-1 gp120. I. Structural and Antigenic Analysis. Molecular Medicine, 2000, 6, 494-508.	4.4	4
46	Anti-Fas (CD95/Apo-I) Autoantibodies and Soluble Fas Levels Concur in T Cell Depletion in HIV Type 1 Infection. AIDS Research and Human Retroviruses, 2001, 17, 603-614.	1.1	4
47	Characterization of a Rare Nonpathogenic Sequence Variant (c.1905C>T) of the Dihydropyrimidine Dehydrogenase Gene (DPYD). International Journal of Biological Markers, 2017, 32, 357-360.	1.8	3
48	Fertility preservation techniques in cervical carcinoma. Medicine (United States), 2022, 101, e29163.	1.0	3
49	Animal-type melanoma: dog or wolf? A review of the literature and a case report. Expert Reviews in Molecular Medicine, 2018, 20, e5.	3.9	2
50	DEAD-Box Helicase 4 (Ddx4)+ Stem Cells Sustain Tumor Progression in Non-Serous Ovarian Cancers. International Journal of Molecular Sciences, 2020, 21, 6096.	4.1	2